Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04269915
Other study ID # CoHSI2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 12, 2020
Est. completion date December 12, 2022

Study information

Verified date April 2024
Source Leiden University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Groups of 3 or 7 volunteers will be exposed to a predetermined number of female Schistosoma mansoni cercariae until 10 volunteers are found infected.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date December 12, 2022
Est. primary completion date April 14, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Subject is aged = 18 and = 45 years and in good health. - Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby. - Subject is able to communicate well with the investigator, is available to attend all study visits. - Subject will remain within Europe (excluding Corsica) during the study period and is reachable by mobile telephone from week 3 to week 8 of the study period. - Subject agrees to refrain from blood donation to "Sanquin" (blood bank) or for other purposes throughout the study period. - For female subjects: subject agrees to use adequate contraception and not to breastfeed for the duration of study. - Subject has signed informed consent. Exclusion Criteria: - Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immune-deficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following: - body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening; - positive human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) screening tests; - the use of immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period; - history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years; - any history of treatment for severe psychiatric disease by a psychiatrist in the past year; - history of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset. - The chronic use of any drug known to interact with praziquantel, artesunate or lumefantrine metabolism (e.g. phenytoin, carbamazepine, phenobarbital, primidon, dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine, amitriptyline, clomipramine, class I-A and III anti-arrythmics, antipsychotics, antidepressants, macrolides, fluoroquinolones, imidazole- and triazole antimycotics, antihistamines) Because lumefantrine may cause extension of QT-time, chronic use of drugs with effect on QT interval are excluded from the study. - For female subjects: positive urine pregnancy test at screening. - Any history of schistosomiasis or treatment for schistosomiasis. - Positive serology for schistosomiasis or elevated serum CAA at screening. - Known hypersensitivity to or contra-indications (including co-medication) for use of praziquantel, artesunate or lumefantrine. - Being an employee or student of the department of parasitology or infectious diseases of the Leiden University Medical Center.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
female Schistosoma mansoni cercariae
Viable female Schistosoma mansoni cercariae of the Puerto Rican strain

Locations

Country Name City State
Netherlands Leiden University Medical Center Leiden

Sponsors (1)

Lead Sponsor Collaborator
Leiden University Medical Center

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Koopman JPR, Houlder EL, Janse JJ, Casacuberta-Partal M, Lamers OAC, Sijtsma JC, de Dood C, Hilt ST, Ozir-Fazalalikhan A, Kuiper VP, Roozen GVT, de Bes-Roeleveld LM, Kruize YCM, Wammes LJ, Smits HH, van Lieshout L, van Dam GJ, van Amerongen-Westra IM, Meij P, Corstjens PLAM, Jochems SP, van Diepen A, Yazdanbakhsh M, Hokke CH, Roestenberg M. Safety and infectivity of female cercariae in Schistosoma-naive, healthy participants: a controlled human Schistosoma mansoni infection study. EBioMedicine. 2023 Nov;97:104832. doi: 10.1016/j.ebiom.2023.104832. Epub 2023 Oct 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number and severity of adverse events, possibly, probably or definitely related to controlled human Schistosoma mansoni infection with female cercariae. 20 weeks
Primary Number of female cercariae at which 100% volunteers show detectable Schistosoma mansoni circulating anodic antigen. 8 weeks
Secondary Average number of weeks until positive serum circulating anodic antigen (CAA) test 8 weeks
Secondary Comparison of peak serum circulating anodic antigen (CAA) concentration in different dose groups 8 weeks
Secondary Humoral (antibody) response profile by protein and glycan array between infected and uninfected individuals 1 year
Secondary Ex vivo lymphocyte profiles using flow cytometry between infected and uninfected individuals 1 year
Secondary Changes over time in commensal gut bacteria by looking at the relative abundance of microbiota using 16S rRNA gene amplicon sequencing after controlled human Schistosoma mansoni infection with female cercariae 1 year
See also
  Status Clinical Trial Phase
Completed NCT04115072 - Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Phase 2/Phase 3
Not yet recruiting NCT05999825 - Sm-p80 Schistosomiasis Challenge Study Phase 2
Completed NCT00463931 - Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana N/A
Completed NCT00215267 - The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda N/A
Completed NCT00276224 - Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia N/A
Completed NCT03845140 - L-PZQ ODT in Schistosoma Infected Children Phase 3
Completed NCT01512277 - Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis Phase 1
Active, not recruiting NCT03910972 - Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Phase 1/Phase 2
Completed NCT05085470 - Repeated Controlled Human Schistosoma Mansoni Infection N/A
Completed NCT02755324 - Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding N/A
Recruiting NCT05868005 - Delivering a Multi-disease Screening Tool to Migrant Populations N/A
Active, not recruiting NCT01869465 - Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis N/A
Completed NCT01553552 - Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal N/A
Recruiting NCT04589390 - Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Phase 2
Completed NCT02868385 - Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Phase 3
Recruiting NCT05762393 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar Phase 1
Not yet recruiting NCT06182176 - Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control N/A
Completed NCT05292391 - Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults Phase 1
Completed NCT03110757 - A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Phase 1
Completed NCT01154049 - Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Phase 1